Effect of statins on the age of onset of age-related macular degeneration

Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2245-2255. doi: 10.1007/s00417-023-06017-0. Epub 2023 Mar 14.

Abstract

Background: This study evaluated the relationship between statin use and the age of onset of age-related macular degeneration (AMD).

Methods: Electronic Health Records from 52,840 patients evaluated at University of California Los Angeles (UCLA) Ophthalmology Clinics and 9,977 patients evaluated at University of California San Francisco (UCSF) Ophthalmology Clinics were screened. Survival analysis was performed using Cox proportional hazards regression models and visualized using Kaplan Meier survival curves, with the following covariates-sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

Results: 5,498 of 52,840 patients at UCLA were diagnosed with AMD. Statin use was associated with a later AMD onset (HR = 0.8823, p < 0.0001), while female sex (HR = 1.0852, p= 00,035), obesity (HR = 1.4555, p < 0.0001), and fluoxetine (HR = 1.3797, p= 0.0003) were associated with an earlier AMD onset. Non-hispanic black (HR = 0.5687, p < 0.0001) and hispanic ethnicities (HR = 0.8269, p= 0.0028) were associated with a later AMD onset. When stratifying for ethnicity, statins, fluoxetine, sex, and obesity were significant only within non-hispanic white subjects. Statin use was significant among patients with dry AMD (HR = 0.8410, p= 0.0001) but not wet AMD (0.9188, p= 0.0351). In the replication cohort, 526 of 9,977 patients at UCSF had AMD. Associations between statins (HR = 0.7643, p= 0.0033), non-hispanic black ethnicity (HR = 0.5043, p= 0.0035), and obesity (HR = 1.9602, p < 0.0001) on AMD onset were confirmed.

Conclusions: In both cohorts, statin use and non-hispanic black ethnicity are associated with a later AMD onset, while obesity with an earlier AMD onset.

Keywords: Age-related Macular Degeneration; Non-neovascular Age-related Macular Degeneration; Regression; Statins.

MeSH terms

  • Age of Onset
  • Female
  • Fluoxetine
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Macular Degeneration*
  • Obesity
  • Retrospective Studies
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Fluoxetine